Business Wire

2023 NAB Show®: Kalray Unveils ngenea®2, A Major Evolution of Its Open Data Management Platform, and Demonstrates It With AWS and Seagate

13.4.2023 20:35:00 EEST | Business Wire | Press release

Share

Kalray (Euronext Growth Paris : ALKAL), today announced the release of ngenea®2, the new version of its open data management and orchestration platform for data-centric applications. Leveraging Kalray’s Data Processor Unit (DPU) acceleration cards and Kalray’s pixstor™ software-defined storage solution, ngenea®2 addresses the challenges faced by a growing number of companies across all industries to be able to process, store, and manage their data faster, more efficiently, and more securely, wherever the data is located and whatever application they use.

ngenea®2 will be demonstrated at NAB 2023 by pixitmedia, Kalray’s subsidiary specialized in storage and data management solutions for the Media & Entertainment industry, in the Amazon (AWS) Innovation Zone and in the booth of its technology partner Seagate.

NEW ADVANCED FEATURES BOOSTED BY KALRAY DPU TECHNOLOGY

An increasing number of companies face challenges in their abilities to store, access, process, and control their data easily and efficiently when working within domains such as HPC, life science, media, finance, and manufacturing, to name a few. ngenea® offers a unique solution to address these challenges. It automates data management to ensure simple and efficient access to data wherever it is needed, on premises or in the cloud, and allows developers and data analysts to run complex data-intensive workflows in an easy and cost-efficient way.

ngenea®2 introduces advanced features to further address these needs. ngenea®2 consolidates data and infrastructure management into a single point of orchestrated control, enabling developers and data scientists to launch new, globally accessible data-centric workflows in seconds, across multiple on-premises, public and private cloud endpoints simultaneously and securely through each phase of their development. ngenea®2 exposes easy-to-use interfaces (“APIs”) to allow integration of third-party storage and application solutions into the ngenea namespace, providing a unified view of and instant global access to real-time data for developers. Moreover, one major evolution of ngenea®2 is its ability to leverage Kalray’s DPUs. With Kalray’s DPUs, ngenea®2 has been designed to give developers the best performance through in-storage NVMe processing and to offer AI-assisted unprecedented levels of insight into unstructured content assets to facilitate data-centric workflows.

DISPLAYING THE LATEST TECHNOLOGIES AT THE MECCA OF BROADCASTING

NAB, held from April 15-19, 2023 in Las Vegas, is one of the largest gatherings of Media & Entertainment (M&E) professionals in the world, featuring the latest technologies, services, and products in the areas of broadcasting, streaming, production, post-production, content creation, and distribution.

At the show, Kalray, through its subsidiary pixitmedia, will demonstrate multiple use cases to highlight how ngenea®2 manages and orchestrates global M&E workflows in diverse environments that include products and services from various technology partners, including AWS and Seagate, but also Adobe, Autodesk, Avid, Blackmagic, and Projective.

DEMONSTRATING AN END-TO-END CLOUD WORKFLOW AT AWS INNOVATION ZONE

At its kiosk in the Amazon Web Services (AWS) Create Innovation Zone (North Hall N2562H), pixitmedia will display a mixed editorial environment in AWS, mirroring a solution that it has in production with a Media & Entertainment Distribution arm of a major motion picture studio.

The demonstration will showcase how Kalray’s pixstor™ and ngenea®2 bring new levels of coherence and efficiency to media production, while improving security, controlling costs, and boosting collaboration. This solution includes an Amazon Elastic Compute Cloud (EC2) workstation in a pixstor™ cloud, with Projective’s Strawberry providing project containerization of a shared storage environment, enabling Adobe, Avid, and Blackmagic DaVinci Resolve participation in the workflow – all using the same core assets.

DEMONSTRATING AUTOMATED MOVEMENT OF MEDIA WITH SEAGATE AND AUTODESK

Also, technology partner Seagate is hosting pixitmedia to display a joint hyperconverged solution with three high-end workstations running Autodesk Flame, Flame Assist, and Blackmagic DaVinci Resolve. The demonstrated solution provides high-performance finishing suites, leveraging high-speed, native access to media data on pixstor™, boosted by Kalray hardware DPU accelerator cards and with ngenea®2 automating the movement of media between a customer NAS, Avid NEXIS, and Tier0 storage.

ABOUT KALRAY

Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric markets, from edge to cloud.

Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.

Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

INVESTOR CONTACTS

E ric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone: + 33 4 76 18 90 71

ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone: + 33 1 53 67 36 72

PRESS CONTACTS

S ylvie DAM
communication@kalrayinc.com
Phone: +33 4 76 18 90 71

ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone: +33 4 72 18 04 92

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 14:38:00 EEST | Press release

Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of the Group on 31 March 2026 is positive at €643 million. The net financial position on 31 December 2025 was positive for €467.6 million. “The results we have presented - said Mario Rizzante, Chairman of Reply - confirm the soundness of the path we have undertaken in recen

Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 14:30:00 EEST | Press release

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that health systems can sustain this approach over time,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “At ISPOR 2026, Organon

SES Announces Extraordinary General Meeting of Shareholders15.5.2026 09:30:00 EEST | Press release

SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun

Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 09:00:00 EEST | Press release

Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership enables agentic AI to scale well beyond pilot deployments. With the Experian Ascend Platform natively connected to the ServiceNow AI Platfo

Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 04:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye